Sugi Predict

Sugi Predict / Compounds / SCHEMBL23210955

SCHEMBL23210955

SCHEMBL23210955

COc1ccc(Cn2nc(-c3ccc(N4CC(N(C)C(=O)O)C4)nc3)c3nc(-c4cccc5c4CCC5)c(OC)cc32)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 4/20 0.35
▸ PDE4A P27815 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ PDE4C Q08493 1/20 0.35
▸ PDE4D Q08499 1/20 0.35
▸ PTGIR P43119 2/20 0.34
▸ PTGDR Q13258 1/20 0.34
▸ MCHR1 Q99705 4/20 0.34
▸ GYS1 P13807 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ BUB1 O43683 4/20 0.33
▸ CACNA1H O95180 1/20 0.33
▸ PTGER1 P34995 1/20 0.32
▸ TUBB4A P04350 1/20 0.32
▸ TUBB P07437 1/20 0.32
▸ TUBA3C P0DPH7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23264034 0.92 RET (0.36) RETPDE4APDE4BPDE4CPDE4D
SCHEMBL29907040 0.92 RET (0.36) RETPDE4APDE4BPDE4CPDE4D
SCHEMBL23211100 0.90 RET (0.35) RETMCHR1MEN1HTTKMT2A
SCHEMBL23211109 0.89 PDE4A (0.35) PDE4APDE4BPDE4CPDE4DPTGIR
SCHEMBL29907154 0.89 RET (0.36) RETPDE4APDE4BPDE4CPDE4D
SCHEMBL23210675 0.89 RET (0.36) RETPDE4APDE4BPDE4CPDE4D
SCHEMBL23211061 0.88 GYS1 (0.35) PDE4APDE4BPDE4CPDE4DPTGIR
SCHEMBL23210958 0.88 RET (0.34) RETPDE4APDE4BPDE4CPDE4D
SCHEMBL29008856 0.88 BUB1 (0.36) RETPDE4APDE4BPDE4CPDE4D
SCHEMBL23210766 0.86 RET (0.44) RETMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 — — US disclosed
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2023-03-21 — — US disclosed
EP-4045151-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-08-24 — — EP disclosed
WO-2021076602-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-04-22 — — WO disclosed
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-04-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 RET 24/4885PDE4A 4056/4885PDE4B 4004/4885
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 RET 24/4885PDE4A 4056/4885PDE4B 4004/4885
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 RET 24/4885PDE4A 4056/4885PDE4B 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.